Fixed combination products of clindamycin 1% (as 1.2% clindamycin phosphate) and benzoyl peroxide (BPO) 5% are commonly used in the treatment of acne vulgaris. Although any given topical acne product may be therapeutically effective, signs and symptoms of cutaneous tolerability may lead to missed applications by the patient, thus limiting adherence to therapy.
BPO and other formulation components such as surfactants, preservatives and high levels of organic solvents can cause cutaneous irritation and dryness.
BPO irritation is dose-dependent. An approach to optimizing the BPO concentration was undertaken to develop a surfactant- and preservative-free, clindamycin and low concentration
The development and optimization of a fixed combination of clindamycin and benzoyl peroxide aqueous gel.
J Drugs Dermatol. 2009 Jul; 8(7): 634-8Bucks D, Sarpotdar P, Yu K, Angel A, Del Rosso J (Hubmed)
Highlight:
Acne Scar Medications | Adult Acne Medications | Sulfur Acne Medications | Oral Acne Medications
The development and optimization of a fixed combination of clindamycin and benzoyl peroxide aqueous gel
